Daiichi Puts New Flu Drug In Phase III Trials For H5N1 Effectiveness
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has begun final-stage trials on a flu drug that could be effective against the bird flu virus. Daiichi's CS-8958 is to undergo its Phase III trial in Japan, Hong Kong, South Korea and Taiwan over the next four months, with influenza A or B patients the participants. The drug is to be tested in comparison with Roche's Tamiflu. Daiichi expects to file an approval application in Japan later next year. Daiichi also has begun separate trials for use of the drug as a pediatric treatment. (Click here for more - a subscription may be required